Corvus PharmaceuticalsCRVS
Recorded

Corvus Pharmaceuticals 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration37 minParticipants9

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon, everyone, and thank you for standing by. Welcome to the Corvus Pharmaceuticals Third Quarter 2026 Business Update and Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. It is now my pleasure to turn the call over to Zack Kubow, Vice President, Investor Relations and Corporate Communications.

Zack KubowVP of Investor Relations and Corporate Communications

Please go ahead, sir. Thank you, operator, and good afternoon, everyone.

Zack KubowVP of Investor Relations and Corporate Communications

Thanks for joining us for the Corvus Pharmaceuticals Third Quarter 2026 Business Update and Financial Results Conference Call. On the call to discuss the results and business updates are Richard Miller, Chief Executive Officer, Leiv Lea, Chief Financial Officer, Jeff Arcara, Chief Business Officer, Ben Jones, Senior Vice President of Pharmaceutical Development, and Suresh Mahabhashyam, Vice President of Clinical Development. The executive team will open the call with some prepared remarks, followed by a question-and-answer period. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements.

Zack KubowVP of Investor Relations and Corporate Communications

Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by those statements, including the risks and uncertainties described in the Corvus quarterly report on Form 10-Q for the quarter ended September 30, 2026, and other filings the company makes with the SEC from time to time. The company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law. With that, I'd like to turn the call over to Leiv Lea.

Leiv LeaCFO

Leif? Thank you, Zach. I will begin with a brief overview of our third quarter 2026 financials and then turn the call over to Richard for a business update.

Leiv LeaCFO

Research and development expenses in the third quarter of 2026 totaled $17.8 million compared to $8.5 million for the same period in 2025. The increase in R&D expenses was primarily due to higher clinical trial costs associated with the development of soquelitinib, as well as an increase in personnel costs. Net loss for the third quarter of 2026 was $20.3 million compared to a net loss of $10.2 million for the same period in 2025. Included in the net loss for the third quarter of 2026 and 2025 were non-cash losses of $0.9 million and $0.3 million, respectively, from Corvus' equity method investment in Angel Pharmaceuticals.

Leiv LeaCFO

Total stock compensation expense for the three months ended September 30, 2026, was $2.8 million compared to $1.2 million for the same period in 2025. As of September 30, 2026, Corvus had cash equivalents, and marketable securities totaling $202.9 million as compared to $56.8 million at December 31, 2025. Cash as of September 30, 2026, included approximately $189.4 million in net proceeds received in a follow-on offering completed in Q1. Also, as announced on June 9, 2026, Corvus invested $5 million in a $13.5 million financing completed by Angel Pharmaceuticals in the second quarter of 2026. Based on our cash position at September 30, 2026, and our current plans, we expect our cash to fund operations into the second quarter of 2028.

Leiv LeaCFO

I'll now turn the call over to Richard, who will discuss our clinical progress and elaborate on our strategy and plans.

Richard MillerCEO

Thank you, Leif, and good afternoon, everyone. Thank you for joining us today for our update call. We are highly focused on soquelitinib, our first-in-class selective ITK inhibitor, and maximizing its potential across a broad range of diseases. We now have soquelitinib in several clinical trials covering a number of areas of medicine. Our priority is advancing our two lead opportunities, the registrational phase III trial in relapsed refractory peripheral T-cell lymphoma and our SIERRA1 phase II trial in moderate to severe atopic dermatitis. Both programs are on track and represent significant opportunities to bring needed new treatment options to patients. Based on soquelitinib's immunologic properties, we are leveraging its novel mechanism of action and broad immunomodulatory profile by strategically expanding its development to include new indications that are currently not well addressed by existing agents.

Richard MillerCEO

This includes our recently initiated trial in hidradenitis suppurativa, our planned asthma trial across T2 and non-T2 patients, and the ongoing trial in ALPS. Combined with the clinical activities in China conducted by our partner, Angel Pharmaceuticals, we anticipate a number of key data readouts and milestones associated with our pipeline over the next year. We are positioned to generate significant value with our pipeline in 2027. I will start with a brief update on our phase III trial in relapsed refractory PTCL. Enrollment is on track with our expectations, with the next milestone being a futility analysis anticipated in the first quarter of 2027. As a reminder, the futility analysis will be conducted by an independent data monitoring committee after a predefined number of progression-free survival, or PFS events, have occurred. This is event-driven, not time-driven.

Richard MillerCEO

Based on the data at that point, the committee will determine whether the study should be continued or terminated for futility based on available safety and efficacy data. Corvus will not announce any safety or efficacy data in conjunction with the interim analysis, but will disclose the committee's decision to continue or discontinue the trial. We remain excited about the potential of soquelitinib to provide a new treatment option for patients with relapsed refractory PTCL, particularly given the challenges with current therapies, none of which are fully FDA approved for this indication. On a related note, there will be an abstract published in the American Society of Hematology, or ASH, Annual Meeting Abstract Supplement of research done by a team from Memorial Sloan Kettering Cancer Center that further supports soquelitinib's mechanism of action.

Richard MillerCEO

The MSK team studied pre- and post-treatment biopsy material from three patients from our phase I trial with cutaneous T-cell lymphomas, a Th2-derived malignancy involving the skin. Using very sophisticated spatial transcriptomics, they showed that response to soquelitinib was associated with blocking GATA3 signaling, the master regulator of Th2 cells, leading to reduced Th2 cells in the skin. I mention this work because it is relevant to the treatment of both PTCL and atopic dermatitis, and adds to the growing body of knowledge supporting the fascinating immunologic properties of soquelitinib. Now for an update on soquelitinib for atopic dermatitis. We remain very excited about the data to date, and we are working to advance development and enrollment in the phase II SIERRA1 trial as quickly as possible.

Richard MillerCEO

The trial was planned to enroll approximately 200 patients, including patients who received prior systemic therapies across three soquelitinib doses and a placebo group. The treatment period is 12 weeks, with a 90-day drug-free follow-up period. Enrollment is on track with our plans, with top-line data anticipated in the third quarter of 2027. Assuming a successful result from SIERRA1, our strategy is to advance soquelitinib into a phase III program, similar to the other approved systemic therapies for atopic dermatitis. This includes a primary endpoint based on EASI score and IGA score at 12 or 16 weeks of therapy compared to a placebo. If our current timelines for SIERRA1 hold, we could be in a position to start a phase III trial in 2028.

Richard MillerCEO

Our goal is to make soquelitinib available as soon as possible for patients, and then expand the clinical evidence and label with post-marketing studies exploring some of its more unique attributes, such as post-treatment response duration. In addition to our efforts, our partner in China, Angel Pharmaceuticals, is conducting a phase I-B/II clinical trial that may provide further evidence in support of soquelitinib's safety and efficacy in atopic dermatitis, while also advancing its development in China. The Angel trial has a similar design to our phase II trial and is open at several leading dermatology centers in China who have been involved in many global registration trials. It is a double-blind, placebo-controlled trial. Angel has completed enrollment in cohort one, which includes 24 patients randomized evenly to soquelitinib doses of 100 milligrams twice per day, 200 milligrams once per day, or placebo.

Richard MillerCEO

This is the same as the lower dose level studied in our phase I trial, but the treatment period is longer at 12 weeks compared to four weeks. Recall, we found evidence of efficacy at these lower doses in our phase I trial with four weeks of therapy. We have been working closely with the Angel team on the trial, including the review of photographic images of disease from every single patient. Based on current timeline, we anticipate Angel and Corvus will announce preliminary data in March 2027. This timing accounts for all patients to complete 12 weeks of therapy and at least a 30-day post-treatment follow-up period, allowing Angel and us to remain blinded up until this point. The physicians and patients will continue to be blinded for the complete 90 days post-treatment, which will allow us to evaluate the durability of response.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day